Gastroesophageal Reflux Disease Market Share

North American Market Forecast

The GERD market in North America is projected to hold a significant revenue share of 35% with a considerable growth rate by 2036. The primary factor for the market expansion is the rising aging population in the region which are more prone to gastrointestinal problems. Furthermore, the rising awareness regarding drug therapies along with the high rate of acceptance of therapy for GERD diseases is also estimated to bring growth opportunities for market expansion in the region.

APAC Market Analysis

The Asia Pacific gastroesophageal reflux disease market is estimated to grow at a notable pace and holds almost 24% market share by the end of the forecast timeline. The rising awareness about health and fitness among the people in the region and the increase in health spending is considered to be the major factor for market growth in the region during the next years. In addition, the expenditure on healthcare from foreign countries is increasing which is favoring the new drug development for GERD treatment in the region.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gastroesophageal reflux disease is estimated at USD 5.24 Billion.

The gastroesophageal reflux disease (GERD) market size was over USD 5.12 Billion in 2023 and is anticipated to reach USD 6.88 Billion by 2036, witnessing around 2.3% CAGR during the forecast period i.e., between 2024-2036. Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.

North America industry is projected to hold 35% of the revenue share in the 2036, owing to rising aging population in the region which are more prone to gastrointestinal problems.

AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease Market Share